Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675844 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
A Phase 2 study of HIV Infections, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT00675844: Completed Phase 2 study of HIV Infections, sponsored by Alexion Pharmaceuticals.
NCT00675844 is a Phase 2 study of HIV Infections that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 7 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00675844, a Phase 2 study of HIV Infections, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
Conditions Studied
Interventions
- DRUG Elvucitabine
Study Locations (5)
Florida
- Clinical Trial Site - Orlando
- Clinical Trial Site - Pensacola
Texas
- Clinical Trial Site - Austin
- Clinical Trial Site - Dallas
New Jersey
- Clinical Trial Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00675844 record still lists
NCT00675844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Elvucitabine is the first listed.
NCT00675844 lists 5 locations in 3 states (Florida, Texas, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00675844 about?
NCT00675844 is a clinical study titled "An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment". Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
What is the current status of trial NCT00675844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-05. Estimated completion is 2010-03.
What conditions does trial NCT00675844 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00675844?
The interventions under investigation include: Elvucitabine (DRUG).
Who is sponsoring clinical trial NCT00675844?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00675844 being conducted?
This trial has 5 study locations across Florida, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00675844's enrollment target sits among peer trials
7 536th of 542 higher than 6 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia